Two-dimensional calibration-free odds design for phase I drug-combination trials

In oncology, it is commonplace to treat patients with a combination of drugs that deliver different effects from different disease-curing or cancer-elimination perspectives. Such drug combinations can often achieve higher efficacy in comparison with single-drug treatment due to synergy or non-overla...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Wenliang Wang, Huaqing Jin, Yan Dora Zhang, Guosheng Yin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-11-01
Subjects:	dose finding drug combination maximum tolerated dose non-parametric method phase I trial design
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1294258/full